NOORT, Sanne, van Oosterwijk JOLIEKE, Jing MA, Elizabeth A R GARFINKLE, Stephanie NANCE, Michael WALSH, Guangchun SONG, Dirk REINHARDT, Martina PIGAZZI, Franco LOCATELLI, Henrik HASLE, Jonas ABRAHAMSSON, Marie JAROŠOVÁ, Charikleia KELAIDI, Sophia POLYCHRONOPOULOU, Marry M VAN DEN HEUVEL-EIBRINK, Maarten FORNEROD, Tanja A GRUBER and C Michel ZWAAN. Analysis of rare driving events in pediatric acute myeloid leukemia. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2023, vol. 108, No 1, p. 48-60. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2021.280250.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Analysis of rare driving events in pediatric acute myeloid leukemia
Authors NOORT, Sanne, van Oosterwijk JOLIEKE, Jing MA, Elizabeth A R GARFINKLE, Stephanie NANCE, Michael WALSH, Guangchun SONG, Dirk REINHARDT, Martina PIGAZZI, Franco LOCATELLI, Henrik HASLE, Jonas ABRAHAMSSON, Marie JAROŠOVÁ (203 Czech Republic, belonging to the institution), Charikleia KELAIDI, Sophia POLYCHRONOPOULOU, Marry M VAN DEN HEUVEL-EIBRINK, Maarten FORNEROD, Tanja A GRUBER and C Michel ZWAAN (guarantor).
Edition haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2023, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 10.100 in 2022
RIV identification code RIV/00216224:14110/23:00131006
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3324/haematol.2021.280250
UT WoS 001000812400004
Keywords in English pediatric acute myeloid leukemia; rare driving events
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/6/2023 08:20.
Abstract
Elucidating genetic aberrations in pediatric acute myeloid leukemia (AML) provides insight in biology and may impact on risk-group stratification and clinical outcome. This study aimed to detect such aberrations in a selected series of samples without known (cyto)genetic aberration using molecular profiling. A cohort of 161 patients was selected from various study groups: DCOG, BFM, SJCRH, NOPHO and AEIOP. Samples were analyzed using RNA sequencing (n=152), whole exome (n=135) and/or whole genome sequencing (n=100). In 70 of 156 patients (45%), of whom RNA sequencing or whole genome sequencing was available, rearrangements were detected, 22 of which were novel; five involving ERG rearrangements and four NPM1 rearrangements. ERG rearrangements showed self-renewal capacity in vitro, and a distinct gene expression pattern. Gene set enrichment analysis of this cluster showed upregulation of gene sets derived from Ewing sarcoma, which was confirmed comparing gene expression profiles of AML and Ewing sarcoma. Furthermore, NPM1-rearranged cases showed cytoplasmic NPM1 localization and revealed HOXA/B gene overexpression, as described for NPM1 mutated cases. Single-gene mutations as identified in adult AML were rare. Patients had a median of 24 coding mutations (range, 7-159). Novel recurrent mutations were detected in UBTF (n=10), a regulator of RNA transcription. In 75% of patients an aberration with a prognostic impact could be detected. Therefore, we suggest these techniques need to become standard of care in diagnostics.
PrintDisplayed: 17/7/2024 03:49